In a more recent retrospective, observational, real-world cohort study, combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists was associated with significant reductions in major adverse cardiovascular events (MACE), heart failure hospitalizations, and progression of kidney disease, supporting the synergistic role of dual therapy in type 2 diabetes management [53]. The gene discussed is SLC5A2; the disease is heart failure.